Table 1 Participant characteristics

From: Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

 

Overall (n = 30), median (range) or n (%)

Cabozantinib + nivolumab (n = 10), median (range) or n (%)

Cabozantinib + nivolumab + CBM588 (n = 20), median (range) or n (%)

P value

Age (years)

65 (36–84)

60 (48–67)

68 (36–84)

0.237

Gender

 Male

20 (67)

5 (50)

15 (75)

0.230

 Female

10 (33)

5 (50)

5 (25)

 

Race

 White

26 (87)

7 (70)

19 (95)

0.563

 Asian

3 (10)

2 (20)

1 (5)

 

 Other

1 (3)

1 (10)

0 (0)

 

Ethnicity

 Non-Hispanic or non-Latinx

15 (50)

4 (40)

11 (55)

0.699

 Hispanic or Latinx

15 (50)

6 (60)

9 (45)

 

Histologic subtype

 Clear cell

26 (87)

8 (80)

18 (90)

0.584

 Clear cell with sarcomatoid features

3 (10)

1 (10)

2 (10)

 

 Papillary

2 (7)

0 (0)

2 (10)

 

 Sarcomatoid dedifferentiation

2 (7)

2 (20)

0 (0)

 

IMDC prognostic risk

 Favorable

12 (40)

3 (30)

9 (45)

0.070

 Intermediate

12 (40)

5 (50)

7 (35)

 

 Poor

6 (20)

2 (20)

4 (20)

 

Nephrectomy

 Yes

20 (67)

6 (60)

14 (70)

0.690

 No

10 (33)

4 (40)

6 (30)

 

Number of metastatic sites

 ≥2

24 (80)

8 (80)

16 (80)

1.000

Most common metastatic sites

 Lung

24 (80)

8 (80)

16 (80)

1.000

 Lymph node

15 (50)

6 (60)

9 (45)

0.699

 Bone

12 (40)

4 (40)

8 (40)

1.000

 Adrenal

5 (17)

0 (0)

5 (25)

0.140

 Liver

3 (10)

2 (20)

1 (5)

0.251

 Pancreas

1 (3)

1 (10)

0 (0)

0.333